Business
GSK - fourth tranche of share buyback programme
GSK plc has announced the commencement of the fourth tranche of its £2 billion share buyback programme, with up to £0.45 billion allocated for this phase. This tranche is expected to begin on 17 February 2026 and conclude by 24 April 2026, with purchases executed on the London Stock Exchange and Cboe Europe. The programme's objective is to return excess capital to shareholders and enhance earnings per share, with shares repurchased to be held as treasury shares. This initiative is part of a broader programme initiated on 24 February 2025, with previous tranches successfully completed. Disclaimer*
About this update from Gsk Plc
[{"type":"text","content":"\n\nIssued: 17 February 2026, London UK\n \n \nGSK plc announces the fourth tranche of share buyback programme\n \n\nOn 24 February 2025, GSK plc (\"GSK\") announced the commencement of a £2 billion share buyback programme (the \"Programme\"), as announced in its 2024 full year results announcement published on 5 February 2025. The Programme is to be implemented over the period to the end of Q2 2026.\nThe first tranche of the Programme (of up to £0.7 billion) commenced on 24 February 2025; the second tranche of the Programme (of up to £0.45 billion) commenced on 4 June 2025; and the third tranche of the Programme (of up to £0.3 billion) commenced on 30 September 2025. The first, second and third tranches of the Programme completed in accordance with their terms.\nGSK announces that the fourth tranche of the Programme of up to £0.45 billion will commence today.\nGSK has entered into a non-discretionary agreement with BNP Paribas S.A. (\"BNPP\"), enabling GSK to buy back ordinary shares of 31¼ pence each in GSK (\"Ordinary Shares\") with an aggregate value of up to £0.45 billion (the \"Fourth Tranche\"). Purchases of Ordinary Shares under the Fourth Tranche are expected to commence on 17 February 2026 and to be completed by 24 April 2026.\nThe purpose of the Programme is to return excess capital to shareholders and reduce the share capital of the company, and it is expected that the implementation of the Programme will enhance earnings per share. Ordinary Shares purchased under the Fourth Tranche will be held as Treasury shares.\nBNPP will make trading decisions in relation to the Fourth Tranche independently of GSK with regard to the timing of purchases. Any purchase of Ordinary Shares by BNPP contemplated by this announcement will be carried out on the London Stock Exchange and/or Cboe Europe Limited through the BXE and CXE order books. Any purchases of Ordinary Shares by GSK from BNPP under the Fourth Tranche will be carried out on the London Stock Exchange.\nThe Fourth Tranche will be effected within certain pre-set parameters and in accordance with GSK's general authority to repurchase shares and will be conducted within the parameters prescribed by the Market Abuse Regulation 596/2014, the Commission Delegated Regulation (EU) 2016/1052 (both as incorporated into UK domestic law by the European Union (Withdrawa...